We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03499236
Previous Study | Return to List | Next Study

Reducing Lung CongestIon Symptoms in Advanced Heart Failure (RELIEVE-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03499236
Recruitment Status : Active, not recruiting
First Posted : April 17, 2018
Last Update Posted : February 27, 2023
Sponsor:
Information provided by (Responsible Party):
V-Wave Ltd

Tracking Information
First Submitted Date  ICMJE March 29, 2018
First Posted Date  ICMJE April 17, 2018
Last Update Posted Date February 27, 2023
Actual Study Start Date  ICMJE September 19, 2018
Estimated Primary Completion Date October 15, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 1, 2021)
  • Safety-Percentage of Treatment patients experiencing major device-related adverse events [ Time Frame: 30-days after randomization ]
    Percentage of Treatment group patients experiencing any device-related Major Adverse Cardiovascular or Neurological Events (MACNE) during the first 30-days after randomization, compared to a pre-specified Performance Goal
  • Effectiveness-Hierarchical composite of death, heart transplant or left ventricular assist device (LVAD) implantation, HF hospitalizations, worsening HF events treated as an outpatient, and change in Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Follow-up duration at endpoint analysis ranges from a minimum of 12 to a maximum of 24 months ]
    Treatment and Control groups will be compared using the Finkelstein-Schoenfeld method
Original Primary Outcome Measures  ICMJE
 (submitted: April 13, 2018)
  • Safety-Percentage of Treatment patients experiencing major device-related adverse events [ Time Frame: 30-days after randomization ]
    Percentage of Treatment group patients experiencing any device-related Major Adverse Cardiovascular or Neurological Events (MACNE) during the first 30-days after randomization, compared to a pre-specified Performance Goal
  • Effectiveness-Hierarchical composite of death, heart transplant or left ventricular assist device (LVAD) implantation, HF hospitalizations, and change in six minute walk test (6MWT). [ Time Frame: Follow-up duration at endpoint analysis ranges from a minimum of 12 to a maximum of 24 months ]
    Treatment and Control groups will be compared using the Finkelstein-Schoenfeld method
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 1, 2021)
  • 6MWT changes [ Time Frame: Baseline to 12 months ]
    6MWT changes
  • KCCQ changes [ Time Frame: Baseline to 12 months ]
    KCCQ changes
  • KCCQ changes [ Time Frame: Baseline through study completion, maximum of five years ]
    KCCQ changes
  • Time to all-cause death, LVAD/Transplant, or heart failure hospitalization [ Time Frame: Baseline through study completion, maximum of five years ]
    Time to all-cause death, LVAD/Transplant, or heart failure hospitalization
  • Time to all-cause death or first heart failure hospitalization [ Time Frame: Baseline through study completion, maximum of five years ]
    Time to all-cause death or first heart failure hospitalization
  • Cumulative heart failure hospitalizations [ Time Frame: Baseline through study completion, maximum of five years ]
    Cumulative heart failure hospitalizations
  • Time to first heart failure hospitalization [ Time Frame: Baseline through study completion, maximum of five years ]
    Time to first heart failure hospitalization
  • Modified Primary Effectiveness Endpoint including all-cause death, LVAD/Transplant, HF Hospitalizations, and worsening HF events treated as outpatient but without KCCQ [ Time Frame: Baseline through study completion, maximum of five years ]
    Modified Primary Effectiveness Endpoint including all-cause death, LVAD/Transplant, HF Hospitalizations, and worsening HF events treated as outpatient but without KCCQ
Original Secondary Outcome Measures  ICMJE
 (submitted: April 13, 2018)
  • Change in 6MWT [ Time Frame: Baseline to 12 months ]
    Comparison between Treatment and Control groups of change in 6MWT
  • Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) [ Time Frame: Baseline to 12 months ]
    Comparison between Treatment and Control groups of change in KCCQ
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Reducing Lung CongestIon Symptoms in Advanced Heart Failure
Official Title  ICMJE RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
Brief Summary The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association (NYHA) functional Class II, Class III, or ambulatory Class IV heart failure (HF), irrespective of left ventricular ejection fraction, who at baseline are treated with guideline-directed drug and device therapies.
Detailed Description This is a prospective, multi-center, 1:1 randomized, patient and observer blinded clinical study, with a Shunt Treatment arm and a non-implant Control arm. A total of approximately 500 patients will be randomized. Patients and all research staff managing the patients after randomization will be blinded during follow-up for a minimum of 12 months to a maximum of 24 months. Control patients will have the opportunity to receive a shunt after 24 months once unblinding occurs, if they provide consent, and continue to meet inclusion/exclusion criteria. All implanted patients will be followed for a total of 5 years from the time of the study device implantation.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomized treatment versus control (1:1). Control patients will be allowed to cross-over at the completion of the blinded phase. A parallel roll-in arm will enroll up to 2 patients per site in an open-label study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
In the randomized cohort, participants, the clinical team, and research staff managing the patient after randomization will be blinded to study assignment.
Primary Purpose: Treatment
Condition  ICMJE Heart Failure
Intervention  ICMJE
  • Device: V-Wave Interatrial Shunt
    The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
  • Other: Control
    Right heart catheterization, invasive echocardiography.
Study Arms  ICMJE
  • Experimental: Treatment
    Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
    Intervention: Device: V-Wave Interatrial Shunt
  • Control
    Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
    Intervention: Other: Control
  • Experimental: Roll in
    Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
    Intervention: Device: V-Wave Interatrial Shunt
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: October 26, 2022)
605
Original Estimated Enrollment  ICMJE
 (submitted: April 13, 2018)
500
Estimated Study Completion Date  ICMJE October 31, 2027
Estimated Primary Completion Date October 15, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Main Inclusion Criteria:

  • Both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) patients
  • NYHA Class II, Class III, or ambulatory Class IV HF
  • Receiving guideline directed medical and device therapy (GDMT) for heart failure
  • For NYHA Class III and ambulatory Class IV, at least one prior hospitalization for heart failure within the last year or elevated BNP level of at least 300 pg/ml or NT-proBNP level of at least 1,500 pg/ml. BNP/NT-ProBNP levels corrected for BMI
  • For NYHA Class II, must have both hospitalization and elevated BNP levels as above specifications

Main Exclusion Criteria:

  • Systolic blood pressure <90 or >160 mmHg
  • Presence of Intracardiac thrombus
  • Pulmonary hypertension with PASP of ≥70 mm/Hg or PVR > 4 WU
  • Significant RV dysfunction - TAPSE <12mm or RVFAC ≤25%
  • Left Ventricular End-Diastolic Diameter (LVEDD) >8cm
  • Moderate to severe aortic or mitral stenosis
  • Stroke or TIA or DVT within the last 6 months
  • eGFR <25 ml/min/1.73 m^2
  • Anatomical anomaly on TEE or ICE that precludes implantation of Shunt across fossa ovalis (FO) of the interatrial septum
  • Inadequate vascular access for implantation of shunt, e.g. femoral venous access for transseptal catheterization and inferior vena cava (IVC) is not patent
  • Hemodynamic heart rhythm, or respiratory instability at time of Final Exclusion Criteria
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Belgium,   Canada,   Germany,   Israel,   Netherlands,   New Zealand,   Poland,   Spain,   Switzerland,   United States
Removed Location Countries Georgia
 
Administrative Information
NCT Number  ICMJE NCT03499236
Other Study ID Numbers  ICMJE CL7018
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Current Responsible Party V-Wave Ltd
Original Responsible Party Same as current
Current Study Sponsor  ICMJE V-Wave Ltd
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Stefan D Anker, MD, PhD University Medical Center Gottingen, Germany
Principal Investigator: JoAnn Lindenfeld, MD Vanderbilt University
Principal Investigator: Josep Rodés-Cabau, MD Université Laval (CRIUCPQ-ULaval)
Principal Investigator: Gregg W Stone, MD Colombia University Medical Center
PRS Account V-Wave Ltd
Verification Date October 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP